Difference between revisions of "Axitinib (Inlyta)"
Warner-admin (talk | contribs) m (Text replacement - "==Diseases for which it is established==" to "==Diseases for which it is established ''(work in progress)''==") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Medullary thyroid cancer medications" to "Category:Thyroid cancer, medullary medications") |
||
| Line 47: | Line 47: | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
[[Category:Thyroid cancer, differentiated medications]] | [[Category:Thyroid cancer, differentiated medications]] | ||
| − | [[Category: | + | [[Category:Thyroid cancer, medullary medications]] |
[[Category:EMA approved in 2012]] | [[Category:EMA approved in 2012]] | ||
[[Category:FDA approved in 2012]] | [[Category:FDA approved in 2012]] | ||
Revision as of 18:33, 29 June 2022
General information
Class/mechanism: Tyrosine kinase inhibitor of vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression, at picomolar concentrations. Inhibits PDGFRA, PDGFRB and c-kit at nanomolar concentrations.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
Patient drug information
- Inlyta Side Effect Tips & Videos (Pfizer)[5]
- Axitinib (Inlyta) package insert[1]
- Axitinib (Inlyta) patient drug information (Chemocare)[6]
- Axitinib (Inlyta) patient drug information (UpToDate)[7]
History of changes in FDA indication
- 1/27/2012: Initial approval for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. (Based on AXIS)
- 5/14/2019: Approved in combination with avelumab for first-line treatment of patients with advanced renal cell carcinoma (RCC). (Approval extended to first-line setting, in combination; based on JAVELIN Renal 101)
- 6/4/2020: Approved in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. (Based on KEYNOTE-426)
History of changes in EMA indication
- 9/3/2012: Initial marketing authorization as Inlyta.
Also known as
- Code names: AG013736, AG-013736
- Brand name: Axishil, Axpero, Inlybest, Inlyta, Luciax
References
- ↑ 1.0 1.1 1.2 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Inlyta manufacturer's website
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Inlyta Side Effect Tips & Videos (Pfizer)
- ↑ Axitinib (Inlyta) patient drug information (Chemocare)
- ↑ Axitinib (Inlyta) patient drug information (UpToDate)